Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine<br />
Study ID Adverse event monitoring Blinding Adverse events<br />
Bousema 2004 KEN<br />
(249 participants)<br />
Karunajeewa 2007 PNG<br />
(249 participants)<br />
Mukhtar 2005 SDN<br />
(160 participants)<br />
Van den Broek 2004 ZAR<br />
(197 participants)<br />
Adverse event monitoring not<br />
described<br />
Adverse event monitoring not<br />
described<br />
Adverse event monitoring not<br />
described<br />
Possible side effects as passively<br />
reported to the examiner were<br />
recorded at each visit (days 0, 1,<br />
2, 3, 7, 14, 21, and 28)<br />
Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine<br />
Single blind (outcome assessors)<br />
AE not reported<br />
Open label Overall comment: No treatment<br />
withdrawals were attributable<br />
to adverse events related<br />
to a study drug<br />
No other significant differences<br />
are noted between treatments<br />
Unclear AE not reported<br />
Open label SAE: No severe adverse events<br />
judged to be related to the treatment<br />
given<br />
Overall comment: Common<br />
complaints were vomiting, diarrhoea,<br />
abdominal pain and<br />
anorexia<br />
<strong>The</strong> frequency of potential adverse<br />
events was low (around<br />
10%) and did not differ between<br />
groups. 1 case of urticaria<br />
occurred with AS+SP<br />
Study ID Adverse event monitoring Blinding Adverse events<br />
Dorsey 2006 UGA<br />
(455 participants)<br />
Assessed at each follow-up visit<br />
(days 0, 1, 2, 3, 7, 14, and 28)<br />
An adverse event defined as any<br />
untoward medical occurrence<br />
Complete blood count and liver<br />
enzymes on days 0 and 14<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
Single blind (outcome assessors)<br />
SAE: 30 serious adverse events<br />
(14/202 AL vs 16 AQ+SP).<br />
Majority were seizures associated<br />
with fever. None considered<br />
probably or definitely related<br />
to study meds.<br />
GI: Anorexia more common<br />
with AQ+SP (P < 0.05). No<br />
significant difference in abdominal<br />
pain, vomiting, or diar-<br />
231